Abstract
The use of illicit substances in large dance parties (“raves”) and nightclubs has become commonplace globally since the 1990s. Having now dispersed from rave sub-cultures, these drugs are available in college bars, house parties, and at concerts. Given this widespread availability, the “typical” club drug user is harder to classify than it had been in the 1990s. One large survey of New York City nightclub attendees attempted to characterize typical users: [1] 1,914 club-going adults aged 18–29 were sampled, of which 70% reported using club drugs at least once and 22% reported recent use. Men were more likely to abuse ketamine and GHB, while female gender was predictive of cocaine use. Gay/bisexual orientation and White race were predictive of use of several club drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kelly BC, Parsons JT, Wells BE. Prevalence and predictors of club drug use among club-going young adults in New York City. J Urban Health. 2006;83(5):884–95.
European Monitoring Centre for Drugs and Drug addiction. The state of the drugs problem in the European Union and Norway: Annual report; 2007.
US Department of Heath and Human Services. National survey on drug use and health. Washington, DC: US Department of Health and Human Services; 2005.
National Institute on Drug Abuse. The monitoring the future national results on adolescent drug use: overview of key findings, 2001. Ann Arbor, MI: University of Michigan Institute for Social Research; 2002.
Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 2001;21(12):1486–513.
Suarez RV, Riemersma R. “Ecstasy” and sudden cardiac death. Am J Forensic Med Pathol. 1988;9:339–41.
Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs. 1986;18:291–304.
Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs. 1998;30(4):371–9.
Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18:319–27.
Wolff K, Hay AWM, Sherlock K, Conner M. Contents of “ecstasy”. Lancet. 1995;346:1100–1.
Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl). 2000;152:230–48.
Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5:79–86.
Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav. 1988;29(2):269–74.
Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics. 2004;45:84–7.
Ferigolo M, Machado AGS, Oliveira NB, et al. Ecstasy intoxication: the toxicological basis for treatment. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:332–41.
Cami J, Farre M, Mas M. Human pharmacology of 3,4- methylenedioxymethamphetamine (“Ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20:455–66.
Mas M, Farre M, de la Torre R. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136–45.
Peroutka SJ. Incidence of recreational use of 3,4- methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on an undergraduate campus. N Engl J Med. 1987;317:1542–3.
Cohen RS. Subjective reports on the effects of the MDMA (‘Ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1137–45.
O’Cain PA, Hletko SB, Ogden BA, et al. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav. 2000;70:141–8.
Walsh T, Carmichale R, Chestnut J. A hyperthermic reaction to ecstasy. Br J Hosp Med. 1994;51:476.
Gill JR, Hayes JA, de Souza IS, et al. Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci. 2002;47:121–6.
Logan ASC, Stickle B, O’Keefe N, Hewitson H. Survival following ‘Ecstasy’ ingestion with a peak temperature of 42°C. Anaesthesia. 1993;48:1017–8.
Hall AP. “Ecstasy” and the anaesthetist. Br J Anaesth. 1997;79:697–8.
Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with “Ecstasy” and “Eve” misuse. J Clin Pathol. 1996;49:149–53.
Schmidt CJ, Black CK, Abbate GM, Taylor VL. MDMA induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85–90.
Nimmo SM, Kennedy BW, Tullett WM, Blyth AS, Dougall JR. Drug-induced hyperthermia. Anaesthesia. 1993;48(10):892–5.
Benowitz NL. Amphetamines. In: Olson KR, editor. Poisoning and drug overdose. 3rd ed. Stamford, CT: Appleton & Lange; 1999. p. 68–70.
Fiege M, Wappler F, Weisshorn R, et al. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine (“ecstasy”). Anesthesiology. 2003;99:1132–6.
Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89(6):1277–96.
Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627–33.
Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.
Ghuran A, van Der Wieken LR, Nolan J. Cardiovascular complications of recreational drugs. BMJ. 2001;323:464–6.
Brody S, Krause C, Veit R, Rau H. Cardiovascular autonomic dysregulation in users of MDMA (“Ecstasy”). Psychopharmacology. 1998;136:390–3.
Kessel B. Hyponatraemia after ingestion of “Ecstasy”. BMJ. 1994;308:414.
Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “Ecstasy” (3,4-MDMA) [letter]. Lancet. 1996;347:1052.
Henry JA, Fallon JK, Kicman AT. Low-dose MDMA (“Ecstasy”) induces vasopressin secretion [letter]. Lancet. 1998;351:1784.
Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (“Ecstasy”) usage. J Clin Gastroenterol. 1995;20:244–7.
Brauer RB, Heidecke CD, Nathrath W, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int. 1997;10:229–33.
Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454–8.
Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in Ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther. 1999;13:129–33.
Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry. 1993;56(9):1036–7.
Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med. 1993;69:874–89.
McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449–54.
McCann UD, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Drug Saf. 1996;15:107–15.
Ranalli E, Bouton R. Intracerebral haemorrhage associated with ingestion of “Ecstasy” [abstr]. Eur Neuropsychopharmacol. 1997;7:S263.
Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1–10.
Klein M, Kramer F. Rave drugs: pharmacological considerations. AANA J. 2004;72:61–7.
Reneman L, Habraken JB, Majoie CB, et al. MDMA (“Ecstasy”) and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol. 2000;21:1001–7.
Richards JR. Rhabdomyolisis and drugs abuse. J Emerg Med. 2000;19:51–6.
Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia. 1992;47:686–7.
Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63:1–22.
Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of “club drugs”. Subst Use Misuse. 2005;40:1189–201.
Okun M, Bartfield RB, Doering PL. GHB toxicity: what you need to know. Emerg Med. 2000;10–23.
Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid: efficacy, potential abuse and dependence in the treatment of alcohol addiction. Alcohol. 2000;20:217–22.
Halkitis PN, Palamar JJ. GHB use among gay and bisexual men. Addict Behav. 2006;31(11):2135–9.
Knudsen K, Greter J, Verdicchio M, et al. A severe outburst of GHB poisonings (gamma-hydroxybutyrate, gamma-hydroxybutyric acid) on the West Coast of Sweden. Mortality numbers ahead of heroin. Clin Toxicol. 2006;44(5):637–8.
Tunnicliff G. Sites of action of gamma-hydroxybutyrate – a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35(6):581–90.
Hedou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Artault JC, et al. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol. 2000;426(4):549–60.
Graeme KA. New drugs of abuse. Emerg Med Clin North Am. 2000;18:625–36.
Galloway GP, Frederick SL, Staggers Jr F. Physical dependence on sodium oxybate. Lancet. 1994;343(8888):57.
Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat. 2002;23:151–6.
McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs. 2001;33(2):143–9.
Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37:147–53.
Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7:278–81.
Rome ES. It’s a rave new world: rave culture and illicit drug use in the young. Clev Clin J Med. 2001;68:541–50.
Berti M, Baciarello M, Troglio R, Fanelli G. Clinical uses of low-dose ketamine in patients undergoing surgery. Curr Drug Targets. 2009;10(8):707–15.
Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30(11):563–9.
Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs. 2001;33:151–8.
Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186–93.
Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36(2):186–97.
Weiner AL, Viera L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18:447–51.
Pal HR, Berry N, Kumar R, et al. Ketamine dependence. Anaesth Intensive Care. 2002;30:382–4.
Ricaurtie GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet. 2005;365:2137–45.
Yu Q, Montes S, Larson D, Watson RR. Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice. Life Sci. 1995;75:29–43.
National Institute on Drug Abuse, Methamphetamine Abuse and addiction: what is Methamphetamine? Bethesda, MD: National Institute of Health; 1998. NIDA research report series, NIH publication 98-4210.
Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377–82.
Karch SB, Stephens BG, Ho CH. Methamphetamine related deaths in San Francisco; demographic, pathologic and toxicologic profiles. J Forensic Sci. 1999;44:359–68.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
DeMaria, S. (2012). Club Drugs. In: Bryson, E., Frost, E. (eds) Perioperative Addiction. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0170-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0170-4_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-0169-8
Online ISBN: 978-1-4614-0170-4
eBook Packages: MedicineMedicine (R0)